Serum Interleukin-22 in Iraqi Patients with Crohn’s Disease: Association with Biologic Treatment Status and Clinical Disease Activity
Kufa Medical Journal · 15.06.2026 · 22 (1)
DOI: 10.36330/kmj.v22.i1.23945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kufa Medical Journal, online erschienen am 15.06.2026. Verfasst von Ghaith Adnan Neamah und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Interleukin-22 (IL-22) is an immunologically relevant cytokine in Crohn’s disease (CD), but its circulating clinical significance remains uncertain. This study evaluated serum IL-22 in Iraqi patients with CD and examined its association with biologic treatment status and disease activity. Methodology: This case-control study included 120 participants divided into three groups: 30 CD patients receiving biologic therapy, 30 untreated CD patients, and 60 healthy controls. Clinical activity for the patients was assessed using the Harvey–Bradshaw Index (HBI). Serum IL-22 concentrations were compared among the groups together with age and body mass index (BMI).
Results
Serum IL-22 levels were significantly elevated in CD patients compared with healthy controls (p = 0.0001). Within the CD cohort, age did not differ significantly between biologically treated and untreated patients (29.33 ± 12.48 vs. 28.70 ± 9.70 years; p = 0.820). In contrast, BMI was significantly higher in the biologic-treatment group (25.44 ± 5.14 vs. 18.52 ± 1.66 kg/m²; p = 0.0001). Patients receiving biologic therapy had markedly lower HBI scores than untreated patients (3.03 ± 1.10 vs. 11.47 ± 3.41; p = 0.0001). Serum IL-22 was also significantly lower in the biologic-treatment group, with median values of 291.38 pg/mL (242.48–367.13) versus 455.36 pg/mL (332.52–562.48) in untreated patients (p = 0.0001.
Conclusion
In this cohort of Iraqi patients with CD, circulating IL-22 levels were significantly higher than in healthy controls. Furthermore, biologic treatment was associated with lower clinical activity and lower circulating IL-22 levels. These findings support a relationship between serum IL-22 and disease state, but they should be interpreted cautiously. Further longitudinal and mechanistic studies are needed to determine whether IL-22 has value as a monitoring biomarker or reflects treatment-modulated inflammatory pathways.
Zitieren
APA
Neamah, G. A., & Salman, K. A. (2026). Serum Interleukin-22 in Iraqi Patients with Crohn’s Disease: Association with Biologic Treatment Status and Clinical Disease Activity. Kufa Medical Journal, 22(1). https://doi.org/10.36330/kmj.v22.i1.23945
Vancouver
Neamah GA, Salman KA. Serum Interleukin-22 in Iraqi Patients with Crohn’s Disease: Association with Biologic Treatment Status and Clinical Disease Activity. Kufa Medical Journal. 2026;22(1). doi:10.36330/kmj.v22.i1.23945
BibTeX
@article{Neamah2026,
author = {Neamah, Ghaith Adnan and Salman, Khawlah Abdallah},
title = {Serum Interleukin-22 in Iraqi Patients with Crohn’s Disease: Association with Biologic Treatment Status and Clinical Disease Activity},
journal = {Kufa Medical Journal},
year = {2026},
volume = {22},
number = {1},
doi = {10.36330/kmj.v22.i1.23945}
}
EUVIMED